Avilar Therapeutics, Inc (MA, USA)
Extracellular protein degradation
Casma Therapeutics, Inc (MA, USA)
Targeted degradation by autophagy
Carbon Biosciences (MA, USA)
Non-AAV, Parvovirus-based vector platform
Catamaran Bio, Inc (MA, USA)
Synthetic innate immunology
DEM BioPharma, Inc (MA, USA)
Inter-cellular CRISPR screening
Mogrify Limited (Cambridge, UK)
Ex vivo/In vivo cell conversion
NeoPhore Limited (Cambridge, UK)
DNA mismatch repair system
Orna Therapeutics Holdings, LLC (MA, USA)
Circular RNA-based cell engineering
Pallando Therapeutics Inc. (CA, USA)
Tissue-sparing protein degraders
PhoreMost Limited (Cambridge, UK)
PROTAC& Peptide-based phenotypic screening
Shinobi Therapeutics Inc. (CA, USA)
Hypoimmune iPSC derived T cell therapy
Solu Therapeutics, Inc (MA, USA)
Antibody-intractable cell surface targets
Somite Therapeutics Inc. (MA, USA)
AI driven cell therapy
Stealth mode Company (Invested in 2022 Feb) (NA)
RNA biology
Syntax Bio, Inc (IL, USA)
Cell differentiation discovery platform
Toregem BioPharma Co., Ltd (Kyoto, Japan)
Antibody-based tooth regeneration
Turn Biotechnologies, Inc (CA, USA)
mRNA/LNP based in vivo cell rejuvenation
Redona Therapeutics, Inc (MA, USA)
Bicycle Therapeutics Ltd (Cambridge, UK)
IPO
Cleave Biosciences, Inc (CA, USA)
CODA Biotherapeutics, Inc (CA, USA)
Crescendo Biologics Ltd (Cambridge, UK)
eFFECTOR Therapeutics, Inc (CA, USA)
SPAC merger
Heartseed Inc (Tokyo, Japan)
IPO
Oncorus, Inc (MA, USA)
IPO
Tizona Therapeutics, Inc (CA, USA)
Trieza Therapeutics, Inc (MA, USA)
Trishula Terapeutics, Inc (CA, USA)
TScan Therapeutics, Inc (MA, USA)
IPO
Viamet Pharmaceuticals, Inc (NC, USA)
F2G Ltd (Manchester,UK)
PanOptica, Inc (NJ, USA)
Contact
Astellas Venture Management LLC
480 Forbes Blvd,
South San Francisco, CA 94080
AVM_web-sm@astellas.com